Document is current
Any future updates will be listed below
-
Authors
Tirosh, Amir https://orcid.org/0000-0003-2210-5906
Khan, Niaz
Vargas-Uricoechea, Hernando
Galstyan, Gagik
Al Shaikh, Abdul Rahman
Makkar, Brij Mohan
Mabunay, Maria Aileen
Melas-melt, Lydie
Pilorget, Valerie
Karalliedde, Janaka
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03703869 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
https://doi.org/10.1007/s13300-022-01266-4
Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region
https://doi.org/10.1007/s13300-024-01537-2
Effectiveness and Safety of Insulin Glargine 300 U/ml in High-Risk Subgroups (Renal Impairment and Older Age ≥ 70 years) of Insulin-Naïve People with Type 2 Diabetes: A Post hoc Analysis of Real-World ATOS Study
https://doi.org/10.1007/s13300-025-01785-w
1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study
https://doi.org/10.2337/db20-1028-p
-
Funding
Funding for this research was provided by:
Sanofi Paris France
- License Information
-
More Information
Article History
Received: 14 May 2025
Accepted: 19 August 2025
First Online: 8 September 2025
Declarations
:
: Amir Tirosh: Member of the ATOS Steering Committee and have received honoraria in relation to the ATOS study; He was a member of the National Diabetes Council; Head of the Diabetes Committee of the Israeli Endocrine Society; received honoraria from Sanofi; grant from Medtronic; consulting fees from Sanofi, NovoNordisk, MSD, Merck, AstraZeneca, Medtronic, Dreamed Diabetes; and received personal fees for participation in advisory boards from Sanofi, Novo-Nordisk, MSD, Merck, AstraZeneca, Bayer. Niaz Khan: Member of the ATOS Steering Committee and have received honoraria in relation to the ATOS study. Hernando Vargas-Uricoechea: Member of the ATOS Steering Committee and have received honoraria in relation to the ATOS study; received honoraria from Sanofi and Abbott; personal fees for participation in advisory boards and funding for attending meetings/travel from Sanofi. Gagik Galstyan: Member of the ATOS Steering Committee and have received honoraria in relation to the ATOS study. Abdul Rahman Al Shaikh and Brij Mohan Makkar: An experts, investigator for the ATOS and have received honoraria in relation to the ATOS study. Lydie Melas-melt: Employee of IVIDATA Life Sciences, Levallois-Perret, France, contracted by Sanofi. Janaka Karalliedde: Received research grants from Astra Zeneca, institution fee from Sanofi and speaker and advisory board fees from Boehringer Ingelheim, Lilly, Astra Zeneca and Daichi Sankyo. Maria Aileen Mabunay: Employee of Sanofi and may hold shares and/or stock options in the company. Valerie Pilorget was an employee of Sanofi at the time of study conduct and may hold stocks/shares in the company.
: ATOS study was conducted in accordance with the guidelines for Good Epidemiology Practice and principles laid down in the 1964 Declaration of Helsinki by the 18th World Medical Assembly and its later amendments. The study is registered at the U.S. National Library of Medicine (Clinicaltrials.gov Number, NCT03703869). The study protocol was reviewed and approved by the Independent Interdisciplinary Ethics Committee on Ethical Review for Clinical Studies in accordance with the local regulations in each participating country/study center. All participants provided written informed consent.
